RxDoctor Payments Data

Michelle Ecker, MD

Internal Medicine · Lower Gwynedd, PANPI 1942295415

Payments from drug & device makers

$3,569in general payments, 2019–2025

Across 66 payments — averaging $54.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$915
  • Johnson & Johnson$513
  • AstraZeneca$397
  • Abbott$334
  • Medtronic$291
  • Pfizer$213
  • plus $905 from 16 others

What the payments were for

  • Food & beverage$3,569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,569 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$136,448
Medicare patients
277
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$35,891
MounjaroTirzepatide17$17,863
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$16,388
OzempicSemaglutide14$12,979
Arnuity ElliptaFluticasone Furoate11$3,468
Rosuvastatin Calcium89$1,800
Celecoxib18$1,583
Levothyroxine Sodium106$1,282
Amlodipine Besylate150$1,271
Atorvastatin Calcium98$1,260
Candesartan Cilexetil12$1,135
Duloxetine Hcl39$1,080
Mirtazapine32$955
Metoprolol Succinate59$917
Bupropion XlBupropion Hcl33$905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$213$35,89124 claims
GSKTrelegy Ellipta, Arnuity Ellipta$30$19,85633 claims
Lilly USA, LLCMounjaro$60$17,86317 claims
Novo NordiskOzempic$119$12,97914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lower Gwynedd

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →